Compare Kroger Co (KR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Recursion Pharmaceuticals Inc — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Kroger Co is far larger — about 16.9× Recursion Pharmaceuticals Inc's market cap, and Kroger Co pays a 2.54% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KR | RXRX | |
|---|---|---|
Market Cap | $36.27B | $2.14B |
Volume | 8,301,523 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $6.79 |
52-Week Low | $55.53 | $2.84 |
Typical Hold Time | 108 Days | 23 Days |
Enterprise Value | $57.69B | $1.66B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.41, up 3.65% with a bullish technical outlook. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, though net margin remains thin at 0.73%. Recent earnings beat expectations in Q2 2026, and the company maintains consistent dividends. Analysts are moderately bullish with a $70.62 consensus target, citing digital growth and operational improvements as key drivers.
KR offers value with low P/S (0.26) and stable cash flow generation, but faces risks from competitive pressures and integration challenges from acquisitions. The stock presents opportunity for investors seeking defensive exposure with dividend income, though margin compression and economic sensitivity warrant caution.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
